<HTML>
<head><title>M2950303.DOC;1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:Times New Roman; COLOR:#000000; MARGIN-TOP:0px"> <div style=WIDTH:576px> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>FORM 8-K</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>CURRENT REPORT PURSUANT<br>TO SECTION 13 or 15(d) OF THE<br>SECURITIES EXCHANGE ACT OF 1934</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>Date of report (Date of earliest event reported): &nbsp;July 15, 2013</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>Medytox Solutions, Inc.<br>(Exact Name of Registrant as Specified in Its Charter)</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>Nevada<br>(State or Other Jurisdiction of Incorporation)</p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=267> <td width=300 /> </tr><tr> <td width=267 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>000-54346</p></td> <td width=300 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>54-2156042</p></td></tr> <tr> <td width=267 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Commission File Number)</p></td> <td width=300 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(I.R.S. Employer Identification No.)</p></td></tr></table> <p style=MARGIN:0px align=center><br></p> <table width=100% style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td> <td width=127 /> </tr><tr> <td style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>400 S. Australian Avenue, Suite 800, West Palm Beach, Florida</p></td> <td width=127 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>33401</p></td></tr> <tr> <td style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Address of Principal Executive Offices)</p></td> <td width=127 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Zip Code)</p></td></tr></table> <p style=MARGIN:0px align=center><br></p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=570 /> </tr><tr> <td width=570 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(561) 855-1626</p></td></tr> <tr> <td width=570 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Registrant&#146;s Telephone Number, Including Area Code)</p></td></tr></table> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px"><br></p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=570 /> </tr><tr> <td width=570 style=MARGIN-TOP:0px valign=top> <p style="PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; MARGIN:0px; PADDING-RIGHT:0px">&nbsp;</p></td></tr> <tr> <td width=570 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Former Name or Former Address, if Changed Since Last Report)</p></td></tr></table> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px"><br></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=justify>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; FONT-FAMILY:Wingdings; MARGIN-TOP:0px" align=justify>o<font style="FONT-FAMILY:Times New Roman"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; FONT-FAMILY:Wingdings; MARGIN-TOP:0px" align=justify>o<font style="FONT-FAMILY:Times New Roman"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; FONT-FAMILY:Wingdings; MARGIN-TOP:0px" align=justify>o<font style="FONT-FAMILY:Times New Roman"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; FONT-FAMILY:Wingdings; MARGIN-TOP:0px" align=justify>o<font style="FONT-FAMILY:Times New Roman"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px"><br><br></p> <p style="FONT-SIZE:8pt; MARGIN:0px" align=justify>{26761716;2}</p> <p style=MARGIN:0px align=justify> <hr> <br></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; PAGE-BREAK-BEFORE:always; MARGIN-TOP:0px"><b>Section 1 <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#150;</font> Registrant's Business and Operations</b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; PADDING-LEFT:48px; MARGIN-TOP:0px"><b>Item 1.01. &nbsp;Entering into a Material Definitive Agreement </b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>As previously reported in the Form 8-K filed on May 21, 2012, on May 14, 2012, Medytox Solutions, Inc. ("Medytox") borrowed $550,000 from TCA Global Credit Master Fund, LP ("TCA") pursuant to the terms of the Senior Secured Revolving Credit Facility Agreement, dated as of April 30, 2012, among Medytox, Medytox Medical Marketing &amp; Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC and TCA. &nbsp;As further previously reported in the Form&nbsp;8-K filed on August 15, 2012, on August 8, 2012, Medytox borrowed an additional $525,000 from TCA pursuant to the terms of Amendment No. 1 to Senior Secured Revolving Credit Facility Agreement, dated as of July 31, 2012. &nbsp;Moreover, as previously reported in the Form 8-K filed on December 17, 2012, on December&nbsp;4, 2012, Medytox borrowed an additional $650,000 from TCA pursuant to the terms of Amendment No.&nbsp;2 to Senior Secured Revolving Credit Facility Agreement, dated as of October&nbsp;31, 2012. &nbsp;In addition, as previously reported in the Form 8-K filed on March 15, 2013, on March 4, 2013, Medytox borrowed an additional $800,000 from TCA pursuant to the terms of Amendment No. 3 to Senior Secured Revolving Credit Facility Agreement, dated as of February 28, 2013 (as so amended, the "Credit Agreement"). &nbsp;On July 15, 2013, Medytox borrowed an additional $500,000 from TCA pursuant to the terms of Amendment No. 4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013 ("Amendment No. 4"). &nbsp;In connection with Amendment No. 4, each of International Technologies, LLC ("International") and Alethea Laboratories, Inc. ("Alethea"), wholly-owned subsidiaries of Medytox, entered into a Guaranty Agreement to guaranty the TCA loan and a Security Agreement to pledge substantially all of its assets to secure its guaranty. &nbsp;The maturity date of the loan was extended to January 15, 2014, subject to TCA's continuing ability to call the loan upon 60 days' notice.</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>Medytox paid certain fees to TCA, as set forth in Amendment No.&nbsp;4.</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>In connection with Amendment No.&nbsp;4, Medytox executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. &nbsp;Except as provided in Amendment No.&nbsp;4, the terms of the Credit Agreement remain in full force and effect.</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>There are no material relationships between Medytox or any of its affiliates and TCA, other than with respect to the Credit Agreement and Amendment No.&nbsp;4. &nbsp;</p><a name=Quickmark /> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>The foregoing is qualified in its entirety by reference to (i)&nbsp;Amendment No.&nbsp;4, a copy of which is filed herewith as Exhibit 10.1, (ii)&nbsp;the Fourth Amended and Restated Revolving Promissory Note, a copy of which is filed herewith as Exhibit 10.2, (iii) the Guaranty Agreement, dated as of July 15, 2013, by International in favor of TCA, a copy of which is filed herewith as Exhibit 10.3, (iv) the Security Agreement, dated as of July 15, 2013, between International and TCA, a copy of which is filed herewith as Exhibit 10.4, (v) the Guaranty Agreement, dated as of July 15, 2013, by Alethea in favor of TCA, a copy of which is filed herewith as Exhibit 10.5, and (vi) the Security Agreement, dated as of July 15, 2013, between Alethea and TCA, a copy of which is filed herewith as Exhibit 10.6.</p> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px" align=justify><br><br></p> <p style="MARGIN-BOTTOM:-2px; FONT-SIZE:8pt; FLOAT:left; MARGIN-TOP:0px; WIDTH:310px">{26761716;2}</p> <p style="MARGIN:0px; TEXT-INDENT:-2px" align=justify>2</p> <p style="CLEAR:left; MARGIN:0px" align=justify> <hr> <br></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; PAGE-BREAK-BEFORE:always; MARGIN-TOP:0px" align=justify><b>Section 2 &#150; Financial Information</b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify><b>Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>The information set forth above in Item 1.01 is incorporated by reference.</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px"><b>Section 9 &#150; Financial Statements and Exhibits</b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; PADDING-LEFT:48px; MARGIN-TOP:0px"><b>Item 9.01. Financial Statements and Exhibits</b></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>(d) &nbsp;Exhibits</p></div> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=293> <td width=297 /> </tr><tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center><u>Exhibit Number</u></p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center><u>Description</u></p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.1</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Amendment No.&nbsp;4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013, among Medytox Solutions, Inc., Medytox Medical Marketing &amp; Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Biohealth Medical Laboratory, Inc., Advantage Reference Labs, Inc., International Technologies, LLC, Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.2</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Fourth Amended and Restated Revolving Promissory Note, dated June 30, 2013 (effective date July 15, 2013), issued by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.3</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Guaranty Agreement, dated as of July 15, 2013, by International Technologies, LLC in favor of TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.4</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Security Agreement, dated as of July 15, 2013, between International Technologies, LLC and TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.5</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Guaranty Agreement, dated as of July 15, 2013, by Alethea Laboratories, Inc. in favor of TCA Credit Master Fund, LP</p></td></tr> <tr> <td width=293 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.6</p></td> <td width=297 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Security Agreement, dated as of July 15, 2013, between Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP</p></td></tr></table> <div style=WIDTH:576px> <p style="MARGIN-BOTTOM:32px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center>&nbsp;</p> <p style="MARGIN-BOTTOM:-2px; FONT-SIZE:8pt; FLOAT:left; MARGIN-TOP:0px; WIDTH:310px">{26761716;2}</p> <p style="MARGIN:0px; TEXT-INDENT:-2px" align=justify>3</p> <p style="MARGIN-BOTTOM:32px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center> <hr> </p> <p style="MARGIN-BOTTOM:32px; FONT-SIZE:12pt; MARGIN-TOP:0px" align=center><b>SIGNATURES</b></p> <p style="MARGIN-BOTTOM:48px; FONT-SIZE:12pt; MARGIN-TOP:0px; TEXT-INDENT:48px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="MARGIN-BOTTOM:-2px; FONT-SIZE:12pt; FLOAT:left; MARGIN-TOP:0px; WIDTH:336px">Date: &nbsp;July 23, 2013</p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px">MEDYTOX SOLUTIONS, INC.</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:336px"><u>/s/ William G. Forhan</u></p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:12pt; PADDING-LEFT:336px; MARGIN-TOP:0px">William G. Forhan,<br>CEO and Chairman<br>(principal executive officer)</p> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px" align=justify><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px">&nbsp;</p> <p style=MARGIN:0px><br><br></p> <p style="MARGIN-BOTTOM:-2px; FONT-SIZE:8pt; FLOAT:left; MARGIN-TOP:0px; WIDTH:310px">{26761716;2}</p> <p style="MARGIN:0px; TEXT-INDENT:-2px" align=justify>4</p> <p style="CLEAR:left; MARGIN:0px" align=justify> <hr> <br></p></div> <div style=WIDTH:624px> <p style="MARGIN-BOTTOM:32px; FONT-SIZE:12pt; PAGE-BREAK-BEFORE:always; MARGIN-TOP:0px" align=center><b>EXHIBIT INDEX</b></p></div> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=319> <td width=319 /> </tr><tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center><u>Exhibit Number</u></p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center><u>Description</u></p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.1</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Amendment No.&nbsp;4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013, among Medytox Solutions, Inc., Medytox Medical Marketing &amp; Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Biohealth Medical Laboratory, Inc., Advantage Reference Labs, Inc., International Technologies, LLC, Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.2</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Fourth Amended and Restated Revolving Promissory Note, dated June 30, 2013 (effective date July 15, 2013), issued by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.3</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Guaranty Agreement, dated as of July 15, 2013, by International Technologies, LLC in favor of TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.4</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Security Agreement, dated as of July 15, 2013, between International Technologies, LLC and TCA Global Credit Master Fund, LP</p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.5</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Guaranty Agreement, dated as of July 15, 2013, by Alethea Laboratories, Inc. in favor of TCA Credit Master Fund, LP</p></td></tr> <tr> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="MARGIN-BOTTOM:6px; FONT-SIZE:12pt; MARGIN-TOP:6px" align=center>10.6</p></td> <td width=319 style=MARGIN-TOP:0px valign=top> <p style="FONT-SIZE:12pt; MARGIN:0px" align=justify>Security Agreement, dated as of July 15, 2013, between Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP</p></td></tr></table> <div style=WIDTH:624px> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br><br></p></div> <div style=WIDTH:576px> <p style="FONT-SIZE:8pt; MARGIN:0px" align=justify>{26761716;2}</p> <p style="FONT-SIZE:8pt; MARGIN:0px" align=center>5</p> <p style=MARGIN:0px align=justify> <hr> <br></p></div></body>
<!-- EDGAR Validation Code: 88A39C98 -->
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "msi8k072313.htm", "secsgml_size_bytes": 18632}]
{"company-data": {"conformed-name": "Medytox Solutions, Inc.", "cik": "0001374536", "assigned-sic": "8734", "irs-number": "542156042", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54346", "film-number": "13982296"}, "business-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401", "phone": "(561) 855-1626"}, "mail-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401"}, "former-company": {"former-conformed-name": "CASINO PLAYERS, INC.", "date-changed": "20060905"}}
M2950303.DOC;1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):  July 15, 2013
Medytox Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Nevada
(State or Other Jurisdiction of Incorporation)
000-54346
54-2156042
(Commission File Number)
(I.R.S. Employer Identification No.)
400 S. Australian Avenue, Suite 800, West Palm Beach, Florida
33401
(Address of Principal Executive Offices)
(Zip Code)
(561) 855-1626
(Registrant's Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
{26761716;2}
Section 1
–
Registrant's Business and Operations
Item 1.01.  Entering into a Material Definitive Agreement
As previously reported in the Form 8-K filed on May 21, 2012, on May 14, 2012, Medytox Solutions, Inc. ("Medytox") borrowed $550,000 from TCA Global Credit Master Fund, LP ("TCA") pursuant to the terms of the Senior Secured Revolving Credit Facility Agreement, dated as of April 30, 2012, among Medytox, Medytox Medical Marketing & Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC and TCA.  As further previously reported in the Form 8-K filed on August 15, 2012, on August 8, 2012, Medytox borrowed an additional $525,000 from TCA pursuant to the terms of Amendment No. 1 to Senior Secured Revolving Credit Facility Agreement, dated as of July 31, 2012.  Moreover, as previously reported in the Form 8-K filed on December 17, 2012, on December 4, 2012, Medytox borrowed an additional $650,000 from TCA pursuant to the terms of Amendment No. 2 to Senior Secured Revolving Credit Facility Agreement, dated as of October 31, 2012.  In addition, as previously reported in the Form 8-K filed on March 15, 2013, on March 4, 2013, Medytox borrowed an additional $800,000 from TCA pursuant to the terms of Amendment No. 3 to Senior Secured Revolving Credit Facility Agreement, dated as of February 28, 2013 (as so amended, the "Credit Agreement").  On July 15, 2013, Medytox borrowed an additional $500,000 from TCA pursuant to the terms of Amendment No. 4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013 ("Amendment No. 4").  In connection with Amendment No. 4, each of International Technologies, LLC ("International") and Alethea Laboratories, Inc. ("Alethea"), wholly-owned subsidiaries of Medytox, entered into a Guaranty Agreement to guaranty the TCA loan and a Security Agreement to pledge substantially all of its assets to secure its guaranty.  The maturity date of the loan was extended to January 15, 2014, subject to TCA's continuing ability to call the loan upon 60 days' notice.
Medytox paid certain fees to TCA, as set forth in Amendment No. 4.
In connection with Amendment No. 4, Medytox executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000.  Except as provided in Amendment No. 4, the terms of the Credit Agreement remain in full force and effect.
There are no material relationships between Medytox or any of its affiliates and TCA, other than with respect to the Credit Agreement and Amendment No. 4.
The foregoing is qualified in its entirety by reference to (i) Amendment No. 4, a copy of which is filed herewith as Exhibit 10.1, (ii) the Fourth Amended and Restated Revolving Promissory Note, a copy of which is filed herewith as Exhibit 10.2, (iii) the Guaranty Agreement, dated as of July 15, 2013, by International in favor of TCA, a copy of which is filed herewith as Exhibit 10.3, (iv) the Security Agreement, dated as of July 15, 2013, between International and TCA, a copy of which is filed herewith as Exhibit 10.4, (v) the Guaranty Agreement, dated as of July 15, 2013, by Alethea in favor of TCA, a copy of which is filed herewith as Exhibit 10.5, and (vi) the Security Agreement, dated as of July 15, 2013, between Alethea and TCA, a copy of which is filed herewith as Exhibit 10.6.
{26761716;2}
2
Section 2 – Financial Information
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The information set forth above in Item 1.01 is incorporated by reference.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits
(d)  Exhibits
Exhibit Number
Description
10.1
Amendment No. 4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013, among Medytox Solutions, Inc., Medytox Medical Marketing & Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Biohealth Medical Laboratory, Inc., Advantage Reference Labs, Inc., International Technologies, LLC, Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP
10.2
Fourth Amended and Restated Revolving Promissory Note, dated June 30, 2013 (effective date July 15, 2013), issued by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP
10.3
Guaranty Agreement, dated as of July 15, 2013, by International Technologies, LLC in favor of TCA Global Credit Master Fund, LP
10.4
Security Agreement, dated as of July 15, 2013, between International Technologies, LLC and TCA Global Credit Master Fund, LP
10.5
Guaranty Agreement, dated as of July 15, 2013, by Alethea Laboratories, Inc. in favor of TCA Credit Master Fund, LP
10.6
Security Agreement, dated as of July 15, 2013, between Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP
{26761716;2}
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  July 23, 2013
MEDYTOX SOLUTIONS, INC.
/s/ William G. Forhan
William G. Forhan,
CEO and Chairman
(principal executive officer)
{26761716;2}
4
EXHIBIT INDEX
Exhibit Number
Description
10.1
Amendment No. 4 to Senior Secured Revolving Credit Facility Agreement, dated as of June 30, 2013, among Medytox Solutions, Inc., Medytox Medical Marketing & Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC, Biohealth Medical Laboratory, Inc., Advantage Reference Labs, Inc., International Technologies, LLC, Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP
10.2
Fourth Amended and Restated Revolving Promissory Note, dated June 30, 2013 (effective date July 15, 2013), issued by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP
10.3
Guaranty Agreement, dated as of July 15, 2013, by International Technologies, LLC in favor of TCA Global Credit Master Fund, LP
10.4
Security Agreement, dated as of July 15, 2013, between International Technologies, LLC and TCA Global Credit Master Fund, LP
10.5
Guaranty Agreement, dated as of July 15, 2013, by Alethea Laboratories, Inc. in favor of TCA Credit Master Fund, LP
10.6
Security Agreement, dated as of July 15, 2013, between Alethea Laboratories, Inc. and TCA Global Credit Master Fund, LP
{26761716;2}
5